Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Empire Petroleum Corp (EP) is expected to report for 3Q. F&M Bank Corp (FMBM) is expected to report for 3Q. Galectin Therapeutics Inc (GALT) is expected to report for 3Q. Gyrodyne LLC (GYRO) is ...

最新研究确定了与长期新冠相关的免疫细胞和蛋白质，或可揭示潜在原因。 阿尔伯塔大学的研究人员发现两种蛋白质，可能成为识别长期新冠患者的标志。这一发现可能为数百万患者提供改善生活质量的治疗方法。

北京市结核病胸部肿瘤研究所改革与发展项目科研耗材购置项目 招标项目的潜在投标人应在北京市政府采购电子交易平台。获取招标文件，并于2024-11-22 13:30（北京时间）前递交投标文件。

Galectin-9 (gal-9) is a protein that belongs to the galectin family. Gal-9 is expressed in cells of the innate and adaptive immune system, including lymphocytes, dendritic cells, giant salivary cells, ...

Genetic studies using the All of Us database identified potential glaucoma-associated genes across different ancestries. APOE and Galectin-3 were studied as biomarkers for microglia activity, with ...

Only history of chronic kidney disease was significantly different between those with and without the composite outcome. The highest tertile of plasma Gal-3 (galectin-3) and urine epidermal growth ...

Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

Galectin Therapeutics Inc. NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today ...